Wednesday, October 4, 2023
Clinical Advances in
There is strong evidence supporting the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in improving thromboembolic outcomes across a range of populations. Despite guideline recommendations for NOACs for the treatment of atrial fibrillation (AF) and venous thromboembolism (VTE), they are still widely underutilized or inappropriately applied. The Clinical Advances in Evolving Anticoagulation in AF and VTE is designed to update healthcare professionals on effective anticoagulation therapy in patients at risk for stroke or VTE.
Supported by an independent educational grant from
Daiichi-Sankyo Europe GmbH
Factors to Consider When Selecting a NOAC and Dosing Considerations
Download
Overview of clinical trial data for novel oral anticoagulants.
Download
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention.
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
See All
Professor of Cardiology
Director, University Cardiology Division
Pisa University Hospital
University of Pisa
Pisa, Italy
Senior Professor of Clinical Neurosciences
Department of Neurology and Stroke Center
University Hospital Essen
University Duisburg
Essen, Germany
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States
Professor of Medicine
Department of Cardiology and Intensive Care Medicine
St. Vincenz Hospital
Paderborn, Germany
Director
General Institute for Clinical Research
Osaka National Hospital
Osaka, Japan
Regents Professor, Medicine and Epidemiology
Dean, College of Public Health
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Professor of Medicine and Biochemistry
Hamilton, Ontario, Canada
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Received grants for clinical research from: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Achelios; Allergan, Inc.; AstraZeneca Pharmaceuticals LP; Bayer Vital; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; CoAxia; Corimmun; Covidien; Daiichi Sankyo, Inc.; D-Pharm; Fresenius SE & Co. KGaA; GlaxoSmithKline; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Knoll; Lilly; MSD; Medtronic, Inc.; MindFrame; Neurobiological Technologies; Novartis Pharmaceuticals Corporation; Novo Nordisk A/S; Paion; Parke-Davis; Pfizer Inc.; Portola Pharmaceuticals, Inc.; Sanofi-Aventis; Schering-Plough; SERVIER; Solvay; Syngis; Talecris; Thrombogenics
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Janssen-Cilag; Lundbeck, Inc.; Novartis Pharmaceuticals Corporation; Sanofi-Aventis; Syngis; Talecris
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Akcea; Amarin Corporation plc.; Amgen Inc.; Bristol-Myers Squibb Company; CVS Caremark; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Pfizer Inc.
Received grants for clinical research from: Amgen Inc.
Other: Honoraria for CME lectures from Amgen Inc.; Daiichi Sankyo, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boston Scientific
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; ITREAS; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Portola Pharmaceuticals, Inc.; Tetherex
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Ionis; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Portola Pharmaceuticals, Inc.